Airway biofilm disease

International Journal of Antimicrobial Agents

Volumn 17, Issue 5, 2001, Pages 351-356

  Kobayashi, Hiroyuki ^a  

^a KYORIN UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Biofilm disease; Diffuse panbronchiolitis; Immune complex; Macrolide

Indexed keywords

ALGINIC ACID; AZITHROMYCIN; BETA LACTAM ANTIBIOTIC; CLARITHROMYCIN; ERYTHROMYCIN; MACROLIDE; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ANTIGEN ANTIBODY COMPLEX; AUTOIMMUNITY; BIOFILM; BRONCHIOLITIS; DRUG EFFICACY; HOST CELL; HUMAN; MICROORGANISM; NONHUMAN; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; RESPIRATORY TRACT DISEASE; RESPIRATORY TRACT INFECTION; REVIEW; SYMPTOM;

ANIMALS; ANTI-BACTERIAL AGENTS; BIOFILMS; GLYCOCALYX; HUMANS; MACROLIDES; PSEUDOMONAS AERUGINOSA; RESPIRATORY SYSTEM; RESPIRATORY TRACT DISEASES; RESPIRATORY TRACT INFECTIONS;

EID: 0035041209     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0924-8579(01)00310-7     Document Type: Review

References (34)

1. The bacterial glycocalyx in nature and disease
2. The biofilm glycocalyx as a resistance factor
3. Therapeutic possibilities for diffuse panbronchiolotis
4. Bacterial biofilm (in Japanese)
5. Pathogenic mechanism of chronic Pseudomonas aeruginosa infections in cystic fibrosis
6. Serum bactericidal effect on Pseudomonas aeruginosa isolates from cystic fibrosis patients
7. Susceptibility of biofilm cells of Pseudomonas aeruginosa to bacterial action of whole blood and serum
8. Pathogenesis of intractable respiratory infection
9. A virulence and altered physiological properties of cystic fibrosis strains of Pseudomonas aeruginosa
10. In vitro regulation of virulence in Pseudomonas aeruginosa associated with genetic rearrangement
11. Phenotypic conversion of Pseudomonas aeruginosa in cystic fibrosis
12. Bacterial biofilm in chronic airway infection
13. Airway biofilm disease: its clinical manifestation and therapeutic possibilities of macrolides
14. The role of immune complex in the pathogenesis of bacterial infections
15. Lipoplysaccharide is present in immune complex isolated from sputum in patients with cystic fibrosis and chronic Pseudomonas aeruginosa lung infection
16. Autoantibodies against bacterial/permeability increasing protein in patients with cystic fibrosis
17. Clinical role of autoantibody against bacterial/permeability increasing protein in chronic airway infection
18. A Review of the recent progress treatment of patients with diffuse panbronchiolitis. Associated with Pseudomonas aeruginosa in human diseases
19. A study on the clinical effect of low-dose, long-term administration of erythromycin on diffuse panbronchiolitis. The therapeutic results of 4 years
20. A study on long-term chemotherapy with erythromycin in patients with chronic lower respiratory infection
21. Long-term therapeutic effect of erythromycin chemotherapy and quinolone antibacterial against diffuse panbronchiolitis-retrospective comparative design
22. A study on long-term administration of TE-031 in patients with diffuse panbronchiolitis
23. Study on azithromycin in treatment of diffuse panbronchiolitis
24. Long-term chemotherapy using erythromycin for chronic lower airway infection: effectiveness of clarithromycin in erythromycin infective cases
25. Influence of macrolides on mucoid alginate biosynthetic enzyme from Pseudomonas aeruginosa
26. A study on long-term chemotherapy with erythromycin in patients with chronic lower respiratory infection
27. A study on the clinical effect of low-dosage, long term administration of erythromycin on diffuse panbronchiohtis. The therapeutic results of 4 years
28. A study on long-term administration of TE-031 in patients with diffuse panbronchiolitis
29. Study on azithromycin in treatment of diffuse panbronchiolitis
30. Suppression of virulence factors of Pseudomonas aeruginosa by erythromycin
31. Effects of erythromycin on cellular and humoral immune functions in vitro and in vivo
32. Erythromycin inhibits the production of elastase by Pseudomonas aeruginosa without affecting its proliferation in vitro
33. Roxithromycin treatment in patients with chronic lower respiratory tract disease